203 related articles for article (PubMed ID: 35799138)
1. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
3. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
[TBL] [Abstract][Full Text] [Related]
4. Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial.
Wei XM; Chen XF; Shu P; Jiang ZW; Wu XY; Zou X; Chen K; Shen B; Hu WW; Lu W; Shen WX; Li L; Wang JY; Zhao FJ; Yin QF; Cheng HB; Gu YH
Medicine (Baltimore); 2020 May; 99(22):e19923. PubMed ID: 32481364
[TBL] [Abstract][Full Text] [Related]
5. Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
Gu Z; Wei G; Zhu L; Zhu L; Hu J; Li Q; Cai G; Lu H; Liu M; Chen C; Ji Y; Li G; Huo J
Evid Based Complement Alternat Med; 2021; 2021():5551568. PubMed ID: 34630609
[No Abstract] [Full Text] [Related]
6. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
9. Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.
Zhou L; Liu R; Huang D; Li H; Ning T; Zhang L; Ge S; Bai M; Wang X; Yang Y; Wang X; Chen X; Gao Z; Luo L; Yang Y; Wu X; Deng T; Ba Y
EClinicalMedicine; 2021 Nov; 41():101157. PubMed ID: 34765950
[TBL] [Abstract][Full Text] [Related]
10. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the Motivational Interviewing-Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment: A Pilot Randomized Controlled Trial.
Kanzawa-Lee GA; Ploutz-Snyder RJ; Larson JL; Krauss JC; Resnicow K; Lavoie Smith EM
Cancer Nurs; 2022 Mar-Apr 01; 45(2):E531-E544. PubMed ID: 34483279
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
Kang L; Tian Y; Xu S; Chen H
J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
[TBL] [Abstract][Full Text] [Related]
14. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
[TBL] [Abstract][Full Text] [Related]
20. Traditional Chinese Medicine syndrome analysis on oxaliplatin-induced peripheral neuropathy and clinical efficacy of Bushen Yiqi formula: a prospective randomized controlled study.
Longci P; Chunhui QI; Xubo S; Yixian H; Xinrong Y; Xianjun S
J Tradit Chin Med; 2023 Oct; 43(6):1234-1242. PubMed ID: 37946486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]